Liver Cancer

Oncology
12
Pipeline Programs
15
Companies
20
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
9
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
480%
Small Molecule
120%
+ 9 programs with unclassified modality

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Bristol Myers Squibb
1 program
1
BrivanibPhase 3Small Molecule1 trial
Active Trials
NCT00825955Completed587Est. Aug 2017
Genentech
GenentechCA - Oceanside
2 programs
2
BevacizumabPhase 2Monoclonal Antibody1 trial
bevacizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT01180959Completed45Est. May 2021
NCT00049322Completed30Est. Feb 2012
Sanofi
SanofiPARIS, France
2 programs
2
OxaliplatinPhase 21 trial
cetuximabPhase 2Monoclonal Antibody3 trials
Active Trials
NCT03026803Terminated4Est. Oct 2014
NCT01451632Completed48Est. Jun 2014
NCT00483405Completed33Est. Dec 2010
+1 more trials
Guerbet
GuerbetFrance - Villepinte
1 program
1
LipiodolPhase 21 trial
Active Trials
NCT01877187Completed39Est. Feb 2020
Novartis
NovartisBASEL, Switzerland
1 program
1
Lu-PSMA-617Phase 21 trial
Active Trials
NCT06852820Not Yet Recruiting10Est. Apr 2027
Pfizer
PfizerNEW YORK, NY
1 program
1
Sunitinib MalatePhase 21 trial
Active Trials
NCT00495625Terminated33Est. Dec 2010
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
cetuximabPhase 2Monoclonal Antibody5 trials
Active Trials
NCT02291289Completed1,044Est. Mar 2021
NCT01910610Active Not Recruiting464Est. Dec 2024
NCT01524978Completed208Est. Oct 2016
+2 more trials
DS
Daiichi SankyoChina - Shanghai
1 program
1
exatecan mesylatePhase 21 trial
Active Trials
NCT00004108CompletedEst. Apr 2005
Nanobiotix
NanobiotixPARIS, France
1 program
1
NBTXR3, IL or IA injection + SBRTPhase 1/21 trial
Active Trials
NCT02721056TerminatedEst. May 2020
E
EisaiChina - Liaoning
1 program
1
OxaliplatinPhase 1/21 trial
Active Trials
NCT00374660Completed63Est. Apr 2007
Verona Pharma
Verona PharmaUK - London
1 program
Minimally invasive liver resectionN/A1 trial
Active Trials
NCT05475054Completed9,963Est. Jul 2022
Knight Therapeutics
Knight TherapeuticsQC - Montréal
1 program
Yttrium 90N/A1 trial
Active Trials
NCT00740753Completed339Est. Apr 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Rochecetuximab
Bristol Myers SquibbBrivanib
NovartisLu-PSMA-617
Rochecetuximab
GuerbetLipiodol
Rochecetuximab
GenentechBevacizumab
Rochecetuximab
SanofiOxaliplatin
PfizerSunitinib Malate
Sanoficetuximab
Rochecetuximab
Sanoficetuximab
Genentechbevacizumab
Daiichi Sankyoexatecan mesylate

Showing 15 of 20 trials with date data

Clinical Trials (20)

Total enrollment: 13,192 patients across 20 trials

NCT01910610Rochecetuximab

Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

Start: Oct 2013Est. completion: Dec 2024464 patients
Phase 3Active Not Recruiting
NCT00825955Bristol Myers SquibbBrivanib

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Start: Feb 2009Est. completion: Aug 2017587 patients
Phase 3Completed
NCT06852820NovartisLu-PSMA-617

68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)

Start: Sep 2025Est. completion: Apr 202710 patients
Phase 2Not Yet Recruiting
NCT02291289Rochecetuximab

A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)

Start: Apr 2015Est. completion: Mar 20211,044 patients
Phase 2Completed
NCT01877187GuerbetLipiodol

Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer

Start: Apr 2013Est. completion: Feb 202039 patients
Phase 2Completed
NCT01524978Rochecetuximab

A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers

Start: Apr 2012Est. completion: Oct 2016208 patients
Phase 2Completed
NCT01180959GenentechBevacizumab

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

Start: Apr 2011Est. completion: May 202145 patients
Phase 2Completed
NCT01326000Rochecetuximab

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer

Start: Apr 2011Est. completion: Dec 2013169 patients
Phase 2Completed
NCT03026803SanofiOxaliplatin

A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer

Start: Nov 2006Est. completion: Oct 20144 patients
Phase 2Terminated
NCT00495625PfizerSunitinib Malate

Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)

Start: Oct 2006Est. completion: Dec 201033 patients
Phase 2Terminated
NCT00483405Sanoficetuximab

Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer

Start: Oct 2006Est. completion: Dec 201033 patients
Phase 2Completed
NCT00297128Rochecetuximab

Preoperative Chemoradiation With Capecitabine and Cetuximab

Start: Oct 2005Est. completion: Nov 201131 patients
Phase 2Completed
NCT00251485Sanoficetuximab

A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

Start: Mar 2004Est. completion: Jun 200582 patients
Phase 2Completed
NCT00049322Genentechbevacizumab

Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery

Start: Jun 2003Est. completion: Feb 201230 patients
Phase 2Completed
NCT00004108Daiichi Sankyoexatecan mesylate

DX-8951f in Treating Patients With Liver Cancer

Start: Sep 1999Est. completion: Apr 2005
Phase 2Completed
NCT02721056NanobiotixNBTXR3, IL or IA injection + SBRT

NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers

Start: Jan 2016Est. completion: May 2020
Phase 1/2Terminated
NCT00374660EisaiOxaliplatin

Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors

Start: Jun 2003Est. completion: Apr 200763 patients
Phase 1/2Completed
NCT01451632Sanoficetuximab

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Start: Oct 2011Est. completion: Jun 201448 patients
Phase 1Completed
NCT05475054Verona PharmaMinimally invasive liver resection

Impact of Minimally Invasive and Open Liver Surgery in Different BMI-classes

Start: Dec 2020Est. completion: Jul 20229,963 patients
N/ACompleted
NCT00740753Knight TherapeuticsYttrium 90

Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an Option

Start: Aug 2004Est. completion: Apr 2021339 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2m ago

Office Administrator

SystImmune
2m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
13m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
16m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
16m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
15 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)